Journal of Pharmacokinetics and Pharmacodynamics

, Volume 39, Issue 5, pp 543–560

# Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor

• Xiaoyu Yan
• Yang Chen
• Wojciech Krzyzanski
Original Paper

## Abstract

The target-mediated drug disposition (TMDD) model has been adopted to describe pharmacokinetics for two drugs competing for the same receptor. A rapid binding assumption introduces total receptor and total drug concentrations while free drug concentrations C A and C B are calculated from the equilibrium (Gaddum) equations. The Gaddum equations are polynomials in C A and C B of second degree that have explicit solutions involving complex numbers. The aim of this study was to develop numerical methods to solve the rapid binding TMDD model for two drugs competing for the same receptor that can be implemented in pharmacokinetic software. Algebra, calculus, and computer simulations were used to develop algorithms and investigate properties of solutions to the TMDD model with two drugs competitively binding to the same receptor. A general rapid binding approximation of the TMDD model for two drugs competing for the same receptor has been proposed. The explicit solutions to the equilibrium equations employ complex numbers, which cannot be easily solved by pharmacokinetic software. Numerical bisection algorithm and differential representation were developed to solve the system instead of obtaining an explicit solution. The numerical solutions were validated by MATLAB 7.2 solver for polynomial roots. The applicability of these algorithms was demonstrated by simulating concentration–time profiles resulting from exogenous and endogenous IgG competing for the neonatal Fc receptor (FcRn), and darbepoetin competing with endogenous erythropoietin for the erythropoietin receptor. These models were implemented in ADAPT 5 and Phoenix WinNonlin 6.0, respectively.

## Keywords

Target-mediated drug disposition Gaddum equation Erythropoietin FcRn Therapeutic antibody

## Notes

### Acknowledgments

This work was supported by the Laboratory for Protein Therapeutics at the University at Buffalo, and Grant GM 57980 from the National Institute of Health.

## Supplementary material

10928_2012_9267_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 kb)
10928_2012_9267_MOESM2_ESM.txt (2 kb)
Supplementary material 2 (TXT 2 kb)
10928_2012_9267_MOESM3_ESM.txt (13 kb)
Supplementary material 3 (TXT 12 kb)
10928_2012_9267_MOESM4_ESM.txt (3 kb)
Supplementary material 4 (TXT 2 kb)
10928_2012_9267_MOESM5_ESM.txt (3 kb)
Supplementary material 5 (TXT 3 kb)
10928_2012_9267_MOESM6_ESM.txt (3 kb)
Supplementary material 6 (TXT 3 kb)

## References

1. 1.
Levy G (1994) Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 56:356–358
2. 2.
Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1–10
3. 3.
Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354:2034–2045
4. 4.
Wang B, Nichol JL, Sullivan JT (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76:628–638
5. 5.
Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725
6. 6.
Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S (2010) Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600–605
7. 7.
Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157–159
8. 8.
Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532
9. 9.
Jin F, Liang M, Wang B, Vainshtein I, Schneider A, Chavez C, Lam B, Faggioni R, Roskos L (2011) Mechanism-based pharmacokinetic and pharmacodynamic modeling of MEDI-575, a monoclonal antibody directed against PDGFRalpha. In: Cynomolgus monkeys. American conference on pharmacometrics, San Diego, CA. http://www.go-acop.org/2011/posters
10. 10.
Yan X, Lowe P, Pigeolet E, Fink M, Berghout A, Balser S, Krzyzanski W (2011) Population pharmacokinetic and pharmacodynamic model of pharmacodynamics-mediated drug disposition (PDMDD) of erythropoiesis stimulating agent. In: American conference on pharmacometrics, San Diego, CA. http://www.go-acop.org/2011/posters
11. 11.
Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589–1596
12. 12.
Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573–591
13. 13.
Kenakin TP (2009) A pharmacology primer: theory application and methods. Elsevier, BurlingtonGoogle Scholar
14. 14.
Abramowitz M, Stegun IA (1964) Handbook of mathematical functions with formulas, graphs, and mathematical tables. U.S. Govt. Print. Off, USAGoogle Scholar
15. 15.
Selby SM (1975) Standard mathematical tables. Chemical Rubber Company Press, FloridaGoogle Scholar
16. 16.
Press WH (1992) Numerical recipes in FORTRAN: the art of scientific computing. Cambridge University Press, CambridgeGoogle Scholar
17. 17.
Anton H, Grobe EM, Rorres C, Grobe CA (1994) Elementary linear algebra: applications version: student solutions manual. Wiley, New YorkGoogle Scholar
18. 18.
Hansen RJ, Balthasar JP (2003) Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92:1206–1215
19. 19.
D’Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los AngelesGoogle Scholar
20. 20.
Vaccaro C, Zhou J, Ober RJ, Ward ES (2005) Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23:1283–1288
21. 21.
Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3–10
22. 22.
Macdougall IC (2005) CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4:436–440
23. 23.
Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830–1834
24. 24.
Woo S, Krzyzanski W, Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849–868
25. 25.
Gross AW, Lodish HF (2006) Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281:2024–2032
26. 26.
Hairer E, Nørsett SP, Wanner G (1993) Solving ordinary differential equations: stiff and differential-algebraic problems. Springer, New YorkGoogle Scholar
27. 27.
Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37:25–47
28. 28.
Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT (2010) Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. The AAPS J 12:729–740
29. 29.
Hayes S, Ouellet D, Zhang J, Wire M, Gibiansky E (2011) Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. J Clin Pharmacol 51(10):1403–1417
30. 30.
Berges A, Sahota T, Barton S, Richards D, Austin D, Zamuner S (2012) Development of a mechanistic PK/PD model to guide dose selection of a combined treatment for systemic amyloidosis. Venice, Italy, p 21, Abstract 2546, www.page-meeting.org/?abstract=2546
31. 31.
Doshi S, Chow A, Perez Ruixo JJ (2010) Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. J Clin Pharmacol 50:75S–90S